Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID‐19

Yaqing Zhou,Tao Han,Jiaxin Chen,Can Hou,Lei Hua,Shu He,Yi Guo,Sheng Zhang,Yanjun Wang,Jinxia Yuan,Chenhui Zhao,Jing Zhang,Qiaowei Jia,Xiangrong Zuo,Jinhai Li,Liansheng Wang,Quan Cao,Enzhi Jia
DOI: https://doi.org/10.1111/cts.12805
2020-05-14
Clinical and Translational Science
Abstract:<p>We aimed to report the clinical and autoimmune characteristics of severe and critical novel coronavirus pneumonia caused by SARS‐CoV‐2. The clinical, autoimmune, and laboratory characteristics of 21 patients who had laboratory‐confirmed severe and critical cases of COVID‐19 from the intensive care unit (ICU) ward of the Huangshi Central Hospital, Hubei Province, China were investigated. A total of 21 patients (13 males and eight females) including eight (38.1%) severe cases and 13 (61.9%) critical cases were enrolled. Cough (90.5%) and fever (81.0%) were the dominant symptoms, and most of them (76.2%) had at least one coexisting disorder on admission. The most common characteristics on chest CT were ground‐glass opacity (100%) and bilateral patchy shadowing (76.2%). The most common findings on laboratory measurements were lymphocytopenia (85.7%), elevated levels of C‐reactive protein (94.7%), and Interleukin‐6 (89.5%). The prevalence of anti‐52 kDa SSA/Ro antibody, anti‐60 kDa SSA/Ro antibody and antinuclear antibody in the cases was 20%, 25% and 50% respectively. In the present work, we retrospectively analyzed the clinical and laboratory data from 21 severe and critical cases with COVID‐19. Autoimmune phenomena exist in COVID‐19 subjects, and the results provide the rationale for a strategy of prevention of dysfunction of immune and optimal immunosuppressive therapy in the future.</p>
What problem does this paper attempt to address?